Medtronic plc has acquired privately-held Bellco, a pioneer in hemodialysis treatment solutions.
Medtronic has acquired Italian-based Bellco, from Charme Capital Partners, manager of the pan-European Charme Funds. Terms of the acquisition were not disclosed.
Medtronic says Bellco’s portfolio will bolster its “legacy renal access business” and will be a foundational component of the recently formed Renal Care Solutions business. The idea is that by partnering with stakeholders in healthcare, Medtronic is better positioned to offer products and services that deliver clinical and economic value to the healthcare system. Medtronic is focused on leading the shift to value based healthcare, which rewards those who can deliver quality healthcare to more people at the most affordable cost.
In its press release announcement Medtronic points out that this acquisition furthers its commitment to improve outcomes, expand therapy access, and optimize costs and efficiencies in end stage renal disease (ESRD).
Bellco has created therapies and systems for the treatment of renal failure, multiple organ failure and sepsis. Its full line of dialyzers and chronic and acute dialysis machines perform dialysis for adult, pediatric and neonatal ESRD patients. For more than 40 years, Bellco has offered advanced blood purification treatments for ESRD patients with chronic and acute kidney injury. The company’s solutions are available in more than 50 countries.
“ESRD patients require dialysis for the remainder of their lives, or until a viable kidney transplant becomes available. We believe Medtronic’s Renal Care Solutions can offer better, more accessible and affordable solutions to the growing population of people living with ESRD,” said Ven Manda, president of Renal Care Solutions, Medtronic.
“The integration of Bellco’s portfolio of solutions will help further advance Medtronic’s efforts to provide comprehensive care for dialysis patients worldwide.”